DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Financials Dr. Sulaiman Al Habib Medical Services Group Company
Equities
4013
SA1510P1UMH1
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 289 SAR | +1.26% |
|
+7.76% | +1.76% |
| Jun. 03 | Dr. Sulaiman Al Habib Medical Services Secures Final License for Hospital Operations in Saudi Arabia | MT |
| May. 19 | Dr. Sulaiman Al Habib Medical Services Declares Q1 Dividend | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 38,150 | 56,490 | 77,210 | 99,400 | 101,150 | - | - |
| Enterprise Value (EV) 1 | 38,150 | 56,609 | 77,663 | 101,963 | 107,038 | 107,115 | 108,254 |
| P/E ratio | 36.1 x | 41.1 x | 46.7 x | 48.5 x | 45.9 x | 37.8 x | 31.5 x |
| Yield | 1.38% | 1.67% | - | - | 1.52% | 1.72% | 1.94% |
| Capitalization / Revenue | 6.51 x | 7.79 x | 9.29 x | 10.5 x | 8.92 x | 7.02 x | 6.29 x |
| EV / Revenue | 6.51 x | 7.81 x | 9.34 x | 10.7 x | 9.44 x | 7.43 x | 6.73 x |
| EV / EBITDA | 26.6 x | 31.8 x | 38.6 x | 42.3 x | 37.4 x | 29.9 x | 25.4 x |
| EV / FCF | 26.9 x | 60.9 x | 58.4 x | -403 x | -140 x | 62.3 x | 43.1 x |
| FCF Yield | 3.72% | 1.64% | 1.71% | -0.25% | -0.71% | 1.61% | 2.32% |
| Price to Book | 7.77 x | 10.6 x | 13.1 x | 15.3 x | 14 x | 12.7 x | 10.8 x |
| Nbr of stocks (in thousands) | 350,000 | 350,000 | 350,000 | 350,000 | 350,000 | - | - |
| Reference price 2 | 109.0 | 161.4 | 220.6 | 284.0 | 289.0 | 289.0 | 289.0 |
| Announcement Date | 2/21/21 | 2/20/22 | 2/21/23 | 2/20/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,862 | 7,250 | 8,311 | 9,508 | 11,334 | 14,416 | 16,076 |
| EBITDA 1 | 1,433 | 1,781 | 2,010 | 2,408 | 2,859 | 3,585 | 4,266 |
| EBIT 1 | 1,115 | 1,466 | 1,700 | 2,096 | 2,316 | 2,922 | 3,497 |
| Operating Margin | 19.02% | 20.22% | 20.46% | 22.04% | 20.44% | 20.27% | 21.75% |
| Earnings before Tax (EBT) 1 | 1,128 | 1,491 | 1,797 | 2,170 | 2,384 | 2,930 | 3,609 |
| Net income 1 | 1,055 | 1,377 | 1,651 | 2,046 | 2,201 | 2,731 | 3,238 |
| Net margin | 18.01% | 18.99% | 19.86% | 21.52% | 19.42% | 18.94% | 20.14% |
| EPS 2 | 3.020 | 3.930 | 4.720 | 5.850 | 6.291 | 7.646 | 9.170 |
| Free Cash Flow 1 | 1,420 | 929.3 | 1,330 | -252.7 | -763.3 | 1,720 | 2,510 |
| FCF margin | 24.23% | 12.82% | 16.01% | -2.66% | -6.74% | 11.93% | 15.61% |
| FCF Conversion (EBITDA) | 99.14% | 52.18% | 66.19% | - | - | 47.98% | 58.84% |
| FCF Conversion (Net income) | 134.57% | 67.5% | 80.59% | - | - | 63% | 77.53% |
| Dividend per Share 2 | 1.500 | 2.700 | - | - | 4.396 | 4.961 | 5.621 |
| Announcement Date | 2/21/21 | 2/20/22 | 2/21/23 | 2/20/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,968 | 1,991 | 2,014 | 2,052 | 2,254 | 2,307 | 2,272 | 2,443 | 2,486 | 2,521 |
| EBITDA | - | 498.7 | - | - | 505.3 | - | 577 | - | - | - |
| EBIT 1 | 396.3 | 422.1 | 414.7 | 436.1 | 427.6 | 510.6 | 498.8 | 552.1 | 534.2 | 556.1 |
| Operating Margin | 20.13% | 21.2% | 20.59% | 21.25% | 18.97% | 22.13% | 21.95% | 22.6% | 21.48% | 22.05% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 383.6 | 390.5 | 398.1 | 420.6 | 441.5 | 489.3 | 487 | 544.8 | 491 | 551 |
| Net margin | 19.49% | 19.61% | 19.77% | 20.5% | 19.59% | 21.21% | 21.43% | 22.3% | 19.75% | 21.85% |
| EPS 2 | 1.090 | - | - | 1.200 | 1.260 | 1.400 | 1.390 | 1.560 | 1.500 | 1.570 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/20/22 | 4/24/22 | 8/7/22 | 10/23/22 | 2/21/23 | 5/7/23 | 8/6/23 | 10/30/23 | 2/20/24 | 4/28/24 |
1SAR in Million2SAR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 119 | 453 | 2,563 | 5,888 | 5,965 | 7,104 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.0667 x | 0.2255 x | 1.064 x | 2.06 x | 1.664 x | 1.665 x |
| Free Cash Flow 1 | 1,420 | 929 | 1,330 | -253 | -763 | 1,720 | 2,510 |
| ROE (net income / shareholders' equity) | 22.7% | 26.9% | 29.4% | 33.1% | 31.9% | 35.1% | 36.6% |
| ROA (Net income/ Total Assets) | 11.8% | 13.6% | 14.1% | 14.4% | 13% | 14.8% | 15.3% |
| Assets 1 | 8,974 | 10,154 | 11,706 | 14,191 | 16,927 | 18,430 | 21,210 |
| Book Value Per Share 2 | 14.00 | 15.30 | 16.80 | 18.50 | 20.60 | 22.80 | 26.90 |
| Cash Flow per Share 2 | - | - | - | 9.270 | 7.190 | 8.530 | 11.30 |
| Capex 1 | 758 | 1,254 | 1,513 | 3,497 | 3,472 | 2,148 | 1,798 |
| Capex / Sales | 12.93% | 17.29% | 18.21% | 36.78% | 30.64% | 14.9% | 11.19% |
| Announcement Date | 2/21/21 | 2/20/22 | 2/21/23 | 2/20/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
289
SAR
Average target price
291.1
SAR
Spread / Average Target
+0.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.76% | 26.97B | |
| +24.66% | 88.38B | |
| -21.76% | 77.56B | |
| +7.94% | 18.45B | |
| -13.50% | 16.57B | |
| +3.23% | 15.81B | |
| +77.51% | 13.65B | |
| +76.96% | 13.06B | |
| +23.02% | 12.55B | |
| +36.67% | 12.56B |
- Stock Market
- Equities
- 4013 Stock
- Financials Dr. Sulaiman Al Habib Medical Services Group Company
